Drug Trial Radar · NCT07393438
Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)
Last checked: Nov 20, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 21, 2026
Primary completion
Feb 28, 2027
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety, tolerability, and preliminary efficacy of acetohydroxamic acid (AHA) capsules combined with short-course regimens (BDLLfxC or BDCZ) in patients with multidrug-resistant tuberculosis (MDR-TB). The primary objectives are to assess the safety and tolerability of AHA combined with short-course regimens, and to determine the recommended phase II dose (RP2D) of AHA. The secondary objectives include evaluating the 8-week sputum culture conversion rate, pharmacokinetic parameters, and exploring DNA damage repair biomarkers as potential indicators of treatment response.
Conditions
- Multidrug-Resistant Tuberculosis
- Rifampicin-resistant Tuberculosis
- MDR-TB
- RR-TB
Interventions
Acetohydroxamic AcidDrug
Acetohydroxamic acid administered according to the protocol-defined dose and schedule, in combination with a short-course anti-tuberculosis regimen.
PlaceboDrug
Matching placebo identical in appearance, packaging, and administration schedule to acetohydroxamic acid, administered with the same short-course anti-tuberculosis regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Mycobacterium tuberculosis sputum bacterial loadTime frame: Baseline to Day 14
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Anhui Chest Hospital
Hefei, Anhui, China
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.